5.02
+0.02(+0.40%)
Currency In USD
| Previous Close | 5 |
| Open | 4.97 |
| Day High | 5.13 |
| Day Low | 4.68 |
| 52-Week High | 5.13 |
| 52-Week Low | 3.36 |
| Volume | 464 |
| Average Volume | 4,431 |
| Market Cap | 187.74M |
| PE | -2.39 |
| EPS | -2.1 |
| Moving Average 50 Days | 4.32 |
| Moving Average 200 Days | 3.94 |
| Change | 0.02 |
If you invested $1000 in Molecular Partners AG (MOLN) since IPO date, it would be worth $255.47 as of February 21, 2026 at a share price of $5.02. Whereas If you bought $1000 worth of Molecular Partners AG (MOLN) shares 3 years ago, it would be worth $796.83 as of February 21, 2026 at a share price of $5.02.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Molecular Partners Announces Presentation of First Imaging and Dosimetry Data of DLL3-Targeting Radiotherapy MP0712 in Patients at TWC 2026
GlobeNewswire Inc.
Feb 02, 2026 6:00 AM GMT
Specific tumor accumulation and attractive biodistribution highly supportive of MP0712 clinical development for treatment of DLL3-expressing cancersDosimetry data highlight Radio-DARPins as vector for precise delivery of potent alpha-emitting isotope
Molecular Partners Highlights Clinical Development Progress and Anticipated Milestones at 44th Annual J.P. Morgan Healthcare Conference
GlobeNewswire Inc.
Jan 11, 2026 8:00 PM GMT
Phase 1/2a study with lead Radio-DARPin MP0712 initiated; first patient dosing expected Q1 2026, initial data anticipated in 2026Full imaging and dosimetry data from MP0712 compassionate care program to be presented at TWC 2026Phase 2 investigator-in
Molecular Partners to Present at 44th Annual J.P. Morgan Healthcare Conference
GlobeNewswire Inc.
Dec 18, 2025 6:00 AM GMT
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics